To continue the state life science industry’s record-setting growth rate, the North Carolina Biotechnology Center, with the help of statewide partners, is building an addition to its Research Triangle Park headquarters.
NC Biotech Center building $10M HQ addition
CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease
PALO ALTO, Calif., August 25, 2009 – CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.
Unlikely treatment identified by Braincells neurogenesis platform improved clinical outcomes in patients suffering from depression
SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). The data were presented at NCDEU 2009, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology. Neurogenesis is the process by which pre-existing stem cells in the hippocampus of the adult brain produce new brain cells, including neurons.
CeNeRx Biopharma completes $9 million financing
June 15, 2009
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced completion of a $9 million financing. The financing includes a $5 million credit facility from MidCap Financial and $4 million in convertible debt from existing investors Aisling Capital, L Capital Partners and Pappas Ventures. CeNeRx plans to use the proceeds to advance its pipeline of promising clinical and preclinical stage compounds for mood disorders, neurodegenerative conditions and pain and spasticity.
Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes
SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).
TargeGen successfully completed enrollment of a multi-center clinical trial of TG101348
SAN DIEGO, May 14, 2009 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
Monmouth, NJ, (May 22, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
Anthera's varespladib meets primary endpoint in phase 2 FRANCIS trial for the treatment of Acute Coronary Syndrome
- Favorable results for secondary endpoints support outcomes benefit
HAYWARD, CA – May 6, 2009 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C). All patients in the FRANCIS trial received once daily doses of 80mg of Lipitor® (atorvastatin calcium), plus 500mg of varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles.
Cardiac "Jackhammer" Destroys Arterial Plaque
LAKEWOOD RANCH, March 30, 2009 — Lakewood Ranch Medical Center is the first acute care center in the area to offer a new high-tech procedure that can take the place of bypass surgery for some patients.
A vibrating catheter blasts its way through stoney plaque deposits the same way a jackhammer cuts through concrete, says Dr. Erick E. Calderon, of Lakewood Cardiovascular Consultants, one of the first doctors in Florida trained to use the new device.
Anthera to continue impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera’s Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol based on favorable interim results.
